|Bid||38.65 x 1100|
|Ask||38.67 x 900|
|Day's Range||38.51 - 39.53|
|52 Week Range||29.99 - 43.08|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||22.64|
|Earnings Date||May 04, 2021|
|Forward Dividend & Yield||1.56 (3.95%)|
|Ex-Dividend Date||Jan 28, 2021|
|1y Target Est||40.69|
Dr. Adrian Burrowes, Family Medicine Phy. & CFP Physicians Group CEO, joined Yahoo Finance to discuss the latest on covid-19.
The COVID-19 vaccine developed by Pfizer and BioNTech is effective at preventing symptomatic and severe disease in people with some chronic illnesses, like diabetes and heart disease, the biggest real-world study showed on Thursday. The analysis of almost 1.2 million people by Israel's largest healthcare provider will offer further hope for countries as they get shots into citizens' arms, particularly those considered vulnerable, and curb the pandemic that has killed more than 3.1 million people. The vaccine was 80% effective against symptomatic infection for people with heart or chronic kidney diseases, 86% for people with type 2 diabetes, 75% for cerebrovascular disease, and 84% for people suffering from immunodeficiency, according to the Clalit Research Institue study.